TargetMol

NGI-1

Product Code:
 
TAR-T7366
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T7366-2mg2mg£99.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7366-5mg5mg£116.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7366-1mL1 mL * 10 mM (in DMSO)£121.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7366-10mg10mg£145.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7366-50mg50mg£262.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7366-100mg100mg£393.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
NGI-1 is a a cell-permeable inhibitor of oligosaccharyltransferase (OST).can effectively reduce virus infectivity without affecting cell viability.
CAS:
790702-57-7
Formula:
C17H22N4O3S2
Molecular Weight:
394.51
Pathway:
Microbiology/Virology
Purity:
0.98
SMILES:
CN(C)S(=O)(=O)c1ccc(N2CCCC2)c(c1)C(=O)Nc1ncc(C)s1
Target:
Virus Protease

References

Lopez-Sambrooks C , Shrimal S , Khodier C , et al. Oligosaccharyltransferase inhibition induces senescence in RTK-driven tumor cells[J]. Nature Chemical Biology, 2016. Lu H , Cherepanova N A , Gilmore R , et al. Targeting STT3A-oligosaccharyltransferase with NGI-1 causes herpes simplex virus 1 dysfunction[J]. The FASEB Journal, 2019.